Background: Patients with diabetes are considered to be at high risk for Dyslipidemia and Hypertension and therefore vulnerable to cardiovascular diseases. This study describes the possible role of Glycated Hemoglobin (HbA1c) and serum lipid profile as a biomarker for detecting cardiovascular diseases. Aim: The Aim of our present work is to study the role of HbA1c as a screening biomarker for Dyslipidemia in patients with Type 2 Diabetes Mellitus (DM) Methodology: Our study consists of 140 Type 2 DM patients between age 40-60 years along with age and sex matched healthy controls. Fasting Blood samples were collected from all participants for measuring Lipid Profile, Blood Sugar (FBS) and HbA1c. Results: In our experimental group, the Mean Concentration of Fasting Blood Glucose(mg/dl), S.Cholesterol (mg/dl), S.Triglyceride (mg/dl), S.HDL (mg/dl) and HbA1c(%) is 142.5±5.2, 256.5±9.5, 215.9±5.2 33.5±6.3 and 9.7±1.0 respectively while in Control group it is 91.5±6, 145.3±8.5, 116.5±7.3, 44.5±3.2 and 5.4±0.5 respectively. Conclusion: HbA1c can be used as a potential biomarker for the prediction of Dyslipidemia and CVD.